Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

被引：0

作者：

A. Luna

L. Pérez-Lamas

C. Boque

P. Giraldo

B. Xicoy

C. Ruiz Nuño

M. Moreno Vega

A. Alvarez-Larrán

A. Salamanca

A. García-Noblejas

F. Vall-Llovera

L. Villalon

N. De las Heras

E. Ramila

M. Pérez-Encinas

B. Cuevas

R. Perez-Lopez

F. Sanchez-Guijo

A. Jiménez-Velasco

S. Lakhwani

L. Felipe Casado

A. Rosell

A. Escola

M. J. Fernández

C. Garcia-Hernandez

C. Cervero

E. Mora

M. Sagüés

S. Suarez-Varela

P. Vélez

P. Carrascosa Mastell

R. F. Bitaube

L. Serrano

M. Cortes

J.A Vera Goñi

J. L. Steegmann

V. Gomez Garcia de Soria

J. M. Alonso-Dominguez

M. Colorado Araujo

A. Paz Coll

J.C Hernandez-Boluda

V. García-Gutiérrez

机构：

[1] Hospital Universitario Ramón y Cajal,Hematology Department

[2] IRYCIS,Institut Catala d’Oncologia

[3] Universidad de Alcala,Department of Medicine, University of Salamanca, Hematology Department

[4] Hospital Duran Y Reynals,undefined

[5] L’Hospitalet de Llobregat,undefined

[6] Hospital Quirón Zaragoza,undefined

[7] Institut Català d’Oncologia-Hospital Germans Trias I Pujol,undefined

[8] Hospital Regional Universitario de Málaga,undefined

[9] Hospital Doctor José Molina Orosa de Lanzarote,undefined

[10] Hospital Clinic de Barcelona,undefined

[11] Hospital de Jerez de La Frontera,undefined

[12] Hospital Universitario de La Princesa,undefined

[13] Hospital Mutua de Terrassa,undefined

[14] Hospital Universitario Fundación Alcorcón,undefined

[15] Hospital Universitario de León,undefined

[16] Hospital Parc Tauli,undefined

[17] Hospital Clínico Universitario de Santiago de Compostela,undefined

[18] Hospital Universitario de Burgos,undefined

[19] Hospital Universitario Clínico Virgen de La Arrixaca,undefined

[20] IBSAL-University Hospital of Salamanca,undefined

[21] Hospital Universitario Carlos Haya,undefined

[22] Hospital Universitario de Canarias,undefined

[23] Hospital Virgen de La Salud,undefined

[24] Hospital Virgen de La Victoria,undefined

[25] Hospital Provincial de Castellón,undefined

[26] Hospital Doctor Peset,undefined

[27] Hospital General de Alicante,undefined

[28] Hospital Virgen de La Luz,undefined

[29] Hospital Universitario Y Politécnico La Fe,undefined

[30] Hospital General de Castellón,undefined

[31] Hospital de Granollers,undefined

[32] Hospital Virgen Macarena,undefined

[33] Hospital Universitario Fundación Jiménez Díaz,undefined

[34] Hospital Universitario Marqués de Valdecilla,undefined

[35] Hospital Universitario Puerto Real,undefined

[36] Hospital Clínico Universitario-INCLIVA,undefined

[37] University of Valencia,undefined

来源：

Annals of Hematology | 2022年 / 101卷

关键词：

Leukemia; Inhibitors; Asciminib ;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Failure of second-generation tyrosine kinase inhibitors (2GTKI) is a challenging situation in patients with chronic myeloid leukemia (CML). Asciminib, recently approved by the US Federal Drug Administration, has demonstrated in clinical trials a good efficacy and safety profile after failure of 2GTKI. However, no study has specifically addressed response rates to asciminib in ponatinib pretreated patients (PPT). Here, we present data on responses to asciminib from 52 patients in clinical practice, 20 of them (38%) with prior ponatinib exposure. We analyzed retrospectively responses and toxicities under asciminib and compared results between PPT and non-PPT patients.

引用

页码：2263 / 2270

页数：7

共 50 条

[21] Real-life incidence of thrombotic events in leukemia patients treated with ponatinib
Nichols, E. Dan
Jabbour, Elias
Jammal, Nadya
Chew, Serena
Bryan, Jeffrey
Issa, Ghayas
Garcia-Manero, Guillermo
Sasaki, Koji
DiPippo, Adam
Kantarjian, Hagop
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (09) : E350 - E352
[22] Asciminib for the Treatment of Patients With Chronic Myeloid Leukemia
Cortes, Jorge
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (04) : 207 - 208
[23] EFFICACY AND SAFETY OF PONATINIB USED IN FRAIL CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS OUTSIDE OF CLINICAL TRIALS
Breccia, M.
Abruzzese, E.
Accurso, V.
Castagnetti, F.
Galimberti, S.
Bonifacio, M.
Gangemi, D.
La Barba, G.
Sora, F.
Tiribelli, M.
Iurlo, A.
Luciano, L.
Gozzini, A.
Pezzullo, L.
Rossi, A. Russo
Sgherza, N.
Foa, R.
HAEMATOLOGICA, 2017, 102 : 89 - 90
[24] Long-Term Follow-Up in Patients With Chronic Myeloid Leukemia Treated With Ponatinib in a Real-World Cohort: Safety and Efficacy Analysis
Osorio, Maria Jose Mela
Moiraghi, Beatriz
Osycka, Maria Victoria
Pavlovsky, Miguel A.
Varela, Ana Ines
Del Prete, Georgina Emilia Bendek
Tosin, Maria Fernanda
Perez, Mariel Ana
Riva, Maria Elisa
Berrios, Roxana Ramirez
Fernandez, Isolda
Massa, Federico Sackmann
Giere, Isabel
Sighel, Carolina
Pavlovsky, Carolina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (03): : 158 - 164
[25] Efficacy and Safety of Nilotinib in First Line Therapy in a Real Life Cohort of Chronic Myeloid Leukemia Patients
Luciano, Luigia
Annunziata, Mario
Esposito, Maria Rosaria
Francesco, Palmieri
Iovine, Maria
Danise, Paolo
Pagliuca, Simona
Giagnuolo, Giovanna
Sica, Antonello
Vallone, Roberto
Spiezia, Marilena
Pane, Fabrizio
BLOOD, 2014, 124 (21)
[26] Evaluation of Efficacy and Safety of Ponatinib as Third-line Treatment in Patients with the Diagnosis of Chronic Phase Chronic Myeloid Leukemia
Patir, Pusem
Soyer, Nur
Vural, Filiz
Saydam, Guray
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2016, 26 (04): : 224 - 226
[27] 5-Year Updates from the Pivotal Phase 2 Ponatinib PACE Trial: Efficacy, Safety and Landmark Analysis in Heavily Pretreated Patients with Chronic-Phase Chronic Myeloid Leukemia
Cortes, Jorge E.
Kantarjian, Hagop M.
Pinilla-Ibarz, Javier
le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Talpaz, Moshe
Baccarani, Michele
Deininger, Michael W.
Hochhaus, Andreas
Hughes, Timothy P.
Shah, Neil P.
Lustgarten, Stephanie
Santillana, Sergio
Rivera, Victor M.
Clackson, Tim
Mueller, Martin C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S307 - S308
[28] "REAL-LIFE" FRONTLINE DASATINIB TREATMENT IN UNSELECTED ELDERLY PATIENTS WITH CHRONIC MYELOID LEUKEMIA
Latagliata, R.
Stagno, F.
Annunziata, M.
Abruzzese, E.
Iurlo, A.
Sgherza, N.
Fava, C.
Gozzini, A.
Luciano, L.
Giglio, G.
Sora, F.
Crescenzi, S. Leonetti
Bocchia, M.
Crugnola, M.
Gugliotta, G.
Avanzini, P.
Galimberti, S.
Feo, C.
Porrini, R.
Pregno, P.
Tiribelli, M.
Rizzo, M.
Endri, M.
Antolino, A.
Breccia, M.
Vigneri, P.
Trawinska, M. M.
Guarini, A.
Alimena, G.
HAEMATOLOGICA, 2015, 100 : 698 - 699
[29] "Real-life" Frontline Dasatinib Treatment in Unselected Elderly Patients with Chronic Myeloid Leukemia
Latagliata, Roberto
Stagno, Fabio
Annunziata, Mario
Abruzzese, Elisabetta
Iurlo, Alessandra
Sgherza, Nicola
Fava, Carmen
Gozzini, Antonella
Giglio, Gianfranco
Sora, Federica
Crescenzi, Sabrina Leonetti
Bocchia, Monica
Crugnola, Monica
Gugliotta, Gabriele
Capodanno, Isabella
Galimberti, Sara
Feo, Costanzo
Porrini, Raffaele
Pregno, Patrizia
Breccia, Massimo
Vigneri, Paolo G.
Trawinska, Malgorzata Monika
Guarini, Attilio
Alimena, Giuliana
BLOOD, 2014, 124 (21)
[30] A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients
Luciano, Luigia
Specchia, Giorgina
Martino, Bruno
Accurso, Vincenzo
Santoro, Marco
Malato, Alessandra
Sgherza, Nicola
Pizzuti, Michele
Stagno, Fabio
Musto, Pellegrino
Guarini, Attilio
De Gregorio, Fiorenza
Basile, Santina
Pane, Fabrizio
BLOOD, 2017, 130

← 1 2 3 4 5 →